RegenCen review

What it is

RegenCen is a physician-led midlife, hormone and regenerative medicine practice with 24 locations — eleven across Michigan, twelve across Florida, and one in Bluffton, South Carolina. Its services run bioidentical hormone therapy for women and men, testosterone therapy, medically guided weight loss with semaglutide and tirzepatide, sermorelin, NAD⁺ as IV drips and IM injections, platelet-rich plasma and platelet-rich fibrin, IV vitamin therapy, musculoskeletal pain treatment, hair restoration and women's sexual health. It is led by founder and chief medical officer Dr. Gustav Lo, MD, with co-founder Courtney Lo, PA, and Menopause Society Certified Practitioners on staff.

How it works

In-person first, with virtual appointments by video or phone for patients located in Michigan and Florida. The clinical philosophy is stated explicitly and is unusual for this board: hormone replacement is treated as the foundation layer, peptides as a refinement applied only after that foundation is in place, and sermorelin specifically is described as most useful for patients already on hormone therapy who have hit a wall on a named complaint — with IGF-1 lab work used to judge whether someone is likely to benefit. Care runs under licensed medical providers with clinical review and guidance from Dr. Gustav Lo, and treatment is self-administered by injection between visits. The disclosure that distinguishes it is the negative one: the practice states it works only with therapies studied extensively and prescribed within a clear legal framework, and explicitly discusses the FDA's restriction on 17 peptide compounds — naming BPC-157, ipamorelin and GHK-Cu — as compounds it does not supply. Two limits to weigh. There is no published price for anything, so cost is entirely a consultation conversation. And this is a regional practice with a wide footprint rather than a national telehealth service.

Pricing transparency

Nothing is published. No price appears for sermorelin, for NAD⁺, for hormone therapy or for GLP-1 medications anywhere on the public site, so we quote no figure and set no floor. For a practice whose model is consultation-led and lab-guided, that is a defensible position — the dose and the protocol genuinely differ per patient, and a headline number would misrepresent it — but it does mean you cannot compare RegenCen against a telehealth platform before booking. Ask three things at the consultation: what a month of sermorelin costs including the IGF-1 lab work that decides whether you start it, what an NAD⁺ IV session costs versus an IM injection and how many are proposed, and whether the comprehensive lab panel the program describes is billed separately. Ask too about medication sourcing, since the site does not state whether its sermorelin is compounded or by whom.

Branded vs compounded

Prescription and physician-supervised, with a licensed provider deciding what is appropriate after lab work. Where medication is compounded it is not FDA-approved, and compounded sterile products are not reviewed by the FDA for purity and potency the way approved drugs are; RegenCen does not state its sourcing publicly. On evidence, the short list is a feature. Sermorelin is a GHRH analogue that stimulates your own pituitary to release growth hormone rather than supplying it, preserving the feedback loop exogenous growth hormone overrides — a real, well-characterised mechanism whose human outcome data thins badly beyond short-term IGF-1 movement, which is precisely why using IGF-1 to select patients is more defensible than selling it to everyone. NAD⁺ delivered by IV or IM has no controlled human outcome trials; the forms with human trial data are the oral precursors NR and NMN, which raise a blood NAD⁺ level rather than demonstrate a clinical benefit. Platelet-rich plasma is autologous — your own concentrated platelets — so it carries no immune-reaction risk, and its outcome evidence varies sharply by indication rather than being uniformly strong. The GLP-1 medications on the same page have the largest randomised evidence base of anything RegenCen offers. Individual results vary.

Pros and watch-outs

The evidence behind what RegenCen prescribes

We grade the molecules, not the marketing. Here is what the human data actually shows for each thing on their menu.

• Sermorelin: a real GHRH drug, read against the anti-aging pitch

  An approved growth-hormone-releasing analog with a pediatric track record — and a longevity case built more on biomarkers than outcomes.

• NAD+ IV therapy: an expensive drip ahead of its evidence

  Clinics sell NAD+ infusions for anti-aging, energy and addiction at $250–$1,500 a session — but there's no controlled trial of IV NAD+, and the real human evidence is for oral precursors, not the drip.

• NAD+ precursors (NR and NMN): what the human trials actually show

  They raise NAD+ and look safe short-term — but human evidence is surrogate-marker level, and no trial shows they extend healthspan.

How RegenCen compares

A few alternatives worth a look, depending on what you’re optimizing for.

• OHOptimized Health

  People near south-west Missouri who want a single NAD⁺ shot at a published per-dose price

  See Optimized Health →
• PRPreventiveMD

  NAD⁺ at a published all-in price from a platform that tells you up front whether it can treat you

  See PreventiveMD →
• PLPlexusDx

  NAD⁺ at a published all-in monthly price with check-ins and no membership on top

  See PlexusDx →